Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential
- 6 November 2014
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 52 (3) , 461-471
Abstract
Xenin-25 is co-secreted with glucose-dependent insulinotropic polypeptide (GIP) from intestinal K-cells following a meal. Xenin-25 is believed to play a key role in glucose homoeostasis and potentiate the insulinotropic effect of GIP.Keywords
This publication has 25 references indexed in Scilit:
- Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25Biochemical Pharmacology, 2012
- Glucagon-like Peptide–1 Analogues for Type 2 Diabetes MellitusDrugs, 2011
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 DiabetesDiabetes Care, 2011
- Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary‐induced obesity and insulin resistanceDiabetes, Obesity and Metabolism, 2010
- Xenin-25 Potentiates Glucose-dependent Insulinotropic Polypeptide Action via a Novel Cholinergic Relay MechanismJournal of Biological Chemistry, 2010
- Therapeutic potential for GIP receptor agonists and antagonistsBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker ratBiochemical and Biophysical Research Communications, 2007
- The peptide hormone xenin induces gallbladder contractions in conscious dogsNeurogastroenterology & Motility, 2006
- GIF biology and fat metabolismLife Sciences, 1999
- Effects of fatty acid chain length and saturation on gastric inhibitory polypeptide release in obese hyperglycaemic (ob/ob) miceBioscience Reports, 1985